Cassava Sciences Stock Plummets 85% After Phase III Study Failure
Cassava Sciences announced on November 25, 2024, that its Phase III ReThink-ALZ study failed to meet primary and secondary endpoints for treating mild to moderate Alzheimer's disease. The trial results indicated that Simufilam did not show superiority over a placebo in improving ADAS-COG12 and ADCS-ADL scores. This news led to an 85% drop in the company’s stock price. Since 2021, the efficacy of Simufilam in reducing β-amyloid protein toxicity has been questioned. Two scientists petitioned the FDA to suspend the trials, citing image manipulation in research papers. An NIH investigation report accused the developers of academic misconduct in multiple publications. FDA reviews found issues with data handling, including improper equipment calibration and inappropriate statistical testing. The researchers were indicted by the DOJ in June 2023 for allegedly defrauding NIH grants of approximately $16 million.
Looking for chemical products? Let suppliers reach out to you!
You May Interested In
β-Nicotinamide Adenine Dinucleotide High Quality NAD+ CAS 53-84-9 Exclusive Production Factory CAS NO.53-84-9
$75/UNIT FOB
CAS 2023788-19-2 Weight Loss Peptide GLP-1 Tirzepatide,Type 2 Diabetes,Freeze Dried Powder 99% Purity Peptides
$260.71/MT FOB
2026-07-16
-
Life Sciences Industry Overview
The coverage spans the global life sciences industry across pharmaceuticals and food & nutrition, tracking the shift from lowest-cost sourcing to supply continuity, quality, and risk management, along with product trends and the growing edge of differentiated, globally capable players.Published in: June.2026
Trade Alert
Delivering the latest product trends and industry news straight to your inbox.
(We'll never share your email address with a third-party.)
Related News
-
Zydus Lifesciences Blocked by Delhi High Court in Cancer Biosimilar Case $9.3 Billion Opdyta Patent Dispute Intensifies
-
Novartis Boosts 2025 Earnings Forecast as US Tariff Risks Loom $23 Billion Investment and $10 Billion Buyback Unveiled
-
Bristol Myers’ Reblozyl Misses Main Goal in Cancer Anemia Study $1.77 Billion Drug Faces Setback but Shows Some Benefits
-
Sanofi’s $2.2 Billion Dynavax Acquisition: Why Big Pharma Is Rebuilding the Global Vaccine Order
-
Sun Pharma’s Ilumya Hits Primary Endpoint in Two Phase 3 Trials for Psoriatic Arthritis $681 Million Drug Shows Significant Improvement at Week 24
-
Platinum Chemotherapy Shortages Expose the Fragility of Essential API Supply
-
Lilly’s U.S. API Investment Highlights a New Phase of Pharma Supply Localization
-
The $6 Billion Gold Rush: Generic Semaglutide Set to Reshape Global Pharma After Patent Cliff
-
The Pill That Could Swallow the Needle: Novo Nordisk Launches Oral Wegovy in U.S. Weight-Loss Revolution
-
McKinsey Pays to Close a Purdue Liability Chapter
Recommend Reading
-
Merck to Lay Off 150 Workers at US Gardasil Plant Amid Sales Weakness
-
Novo Nordisk Launches Wegovy in South Africa One in Two Adults Faces Obesity as GLP-1 Drug Competition Heats Up
-
Eli Lilly Strikes $1.3 Billion AI Deal with Superluminal for Next-Gen Obesity Drugs Targets GPCR Breakthrough
-
FDA Approves Precigen’s Papzimeos Immunotherapy 51 Percent of RRP Patients Avoid Surgery for One Year
-
Eli Lilly to Raise UK Mounjaro Price 170 Percent Monthly Cost Jumps from £122 to £330
-
Sodium Nitrate: Fertilizer, Food Curing, and Explosive History
-
Cabot Launches 95F Conductive Additive to Boost Lithium Battery Life for Energy Storage Demands Soar
-
February Shandong Asphalt Market First Declines Then Rises
-
Corn’s Surprise Surge: Export Fireworks Ignite Bullish Sentiment
-
Wacker Invests 300 Million Euros in New Semiconductor-Grade Polysilicon Production Line in Germany